| Autor: |
Pfaller, M. A., Mendes, R. E., Sader, H. S., Castanheira, M., Carvalhaes, C. G. |
| Zdroj: |
Journal of Chemotherapy; November 2023, Vol. 35 Issue: 8 p689-699, 11p |
| Abstrakt: |
AbstractTo assess oritavancin in vitroactivity against clinically relevant Gram-positive pathogens in European (EU) hospitals, a total of 51,531 consecutive and unique clinical isolates collected in 2010–2019 were evaluated. All isolates were tested by CLSI broth microdilution methods. The key resistance phenotypes differed considerably between Eastern Europe (E-EU) and Western Europe (W-EU), respectively: methicillin-resistant (MR) Staphylococcus aureus27.7%/22.9%; multidrug resistant (MDR) S. aureus, 19.7%/15.2%; MR coagulase-negative staphylococci, 77.3%/61.9%; vancomycin-resistant enterococci (E. faecium), 44.2%/20.9%; and MDR E. faecium, 63.8%/55.4%. There were no substantive differences in oritavancin minimum inhibitory concentration (MIC) values for the different species/organism groups over time or by EU region. Oritavancin inhibited 99.9% and 99.1% of all S. aureusand coagulase-negative staphylococci at 0.12 mg/L, respectively, and all isolates of E. faecalisand E. faeciumat ≤0.5 mg/L. Oritavancin susceptibility rates against β-hemolytic and Viridans group streptococci isolates were 98.1% and 99.4%, respectively. Oritavancin had potent activity in vitroagainst this contemporary collection of European Gram-positive isolates from 2010 to 2019. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
